Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of NephrologyBusiness Wire • 11/06/23
Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of RheumatologyBusiness Wire • 10/19/23
Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics SymposiumBusiness Wire • 10/16/23
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event ConferencesBusiness Wire • 09/20/23
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor ConferenceBusiness Wire • 08/30/23
Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesBusiness Wire • 08/09/23
Equillium to Present at the Jefferies Global Healthcare & LD Micro Invitational ConferencesBusiness Wire • 06/01/23
Equillium: A Negative EV Biotech With Compelling Programs And Cash 'Til At Least 2025; Worth A LookSeeking Alpha • 05/12/23
Equillium Reports First Quarter 2023 Financial Results and Provides Clinical UpdatesBusiness Wire • 05/11/23
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow TransplantationBusiness Wire • 04/24/23
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development UpdatesBusiness Wire • 03/23/23
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease ConferenceBusiness Wire • 03/22/23
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTRBusiness Wire • 02/17/23
Equillium to Present at the SVB Securities Annual Global Healthcare ConferenceBusiness Wire • 02/07/23
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRBusiness Wire • 01/13/23
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger AgreementBusiness Wire • 12/23/22
Equillium's Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative ColitisBusiness Wire • 12/16/22
Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of ItolizumabBusiness Wire • 12/06/22
Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical UpdatesBusiness Wire • 11/14/22